Evidence map›Paper›PMID 30411662›Full record

SynthesisTechnology in cancer research & treatment2018

Prognostic Value of Mismatch Repair Genes for Patients With Colorectal Cancer: Meta-Analysis.

Jiang-Tao Hou, Li-Na Zhao, Ding-Jun Zhang, Dong-Yong Lv, Wei-Ling He, Bin Chen, Hui-Biao Li, Pei-Ru Li, Li-Zhen Chen, Xin-Lin Chen

Abstract readMeta-Analysis
In one paragraph

Synthesis in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. InoperableMolecular and clinical oncology · 2022
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiang-Tao Hou1 The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Li-Na Zhao1 The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Ding-Jun Zhang2 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Dong-Yong Lv3 Guangzhou University of Chinese Medicine, Guangzhou, China.
Wei-Ling He4 The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Bin Chen1 The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Hui-Biao Li1 The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Pei-Ru Li2 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Li-Zhen Chen5 School of Nursing Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xin-Lin Chen6 School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.ORCID 0000-0002-2650-8051

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA mismatch repair was proposed to play a pivotal role in the development and prognosis of colorectal cancer. However, the prognostic value of mismatch repair on colorectal cancer is still unknown. The PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched. The articles about mismatch repair (including hMLH1, hMSH2, hMSH3, hMSH6, hPMSH1, and hPMSH2) deficiency for the prognosis of patients with colorectal cancer were included in the study. The hazard ratio and its 95% confidence interval were used to measure the impact of mismatch repair deficiency on survival time. Twenty-one articles were included. The combined hazard ratio for mismatch repair deficiency on overall survival was 0.59 (95% confidence interval: 0.50-0.69) and that on disease-free survival was 0.57 (95% confidence interval: 0.43-0.75). In subgroup analysis, there were a significant association between overall survival and mismatch repair deficiency in Asian studies (hazard ratio: 0.67; 95% confidence interval: 0.50-0.91) and Western studies (hazard ratio: 0.56; 95% confidence interval: 0.46-0.67). For disease-free survival, the hazard ratios in Asian studies and Western studies were 0.55 (95% confidence interval: 0.38-0.81) and 0.62 (95% confidence interval: 0.50-0.78), respectively. Our meta-analysis indicated that mismatch repair could be used to evaluate the prognosis of patients with colorectal cancer.

Indexed as

AdultAgedAged, 80 and overColorectal NeoplasmsDisease-Free SurvivalDNA Mismatch RepairFemaleHumansMaleMiddle AgedNeoplasm ProteinsPrognosisYoung AdultNeoplasm Proteinscolorectal cancerdisease-free survivalDNA mismatch repair (MMR)meta-analysisoverall survivalprognosis

Identifiers

PMID30411662
PMCPMC6259062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.